DongKook Pharmaceutical Co. Ltd (086450) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) has a cash flow conversion efficiency ratio of 0.031x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩23.53 Billion ≈ $15.95 Million USD) by net assets (₩763.74 Billion ≈ $517.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DongKook Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how DongKook Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DongKook Pharmaceutical Co. Ltd (086450) total liabilities for a breakdown of total debt and financial obligations.
DongKook Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKook Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leifheit Aktiengesellschaft
F:LEI
|
0.097x |
|
Limes Schlosskliniken AG
XETRA:LIK
|
0.135x |
|
Oncolytics Biotech Inc
TO:ONC
|
-0.899x |
|
Excelliance MOS
TWO:5299
|
0.024x |
|
PT Satu Visi Putra Tbk
JK:VISI
|
-0.009x |
|
Casa de Bolsa Finamex S.A.B. de C.V
MX:FINAMEXO
|
-0.443x |
|
Dynagas LNG Partners LP
NYSE:DLNG
|
0.044x |
|
Alan Allman Associates SA
PA:AAA
|
0.275x |
Annual Cash Flow Conversion Efficiency for DongKook Pharmaceutical Co. Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of DongKook Pharmaceutical Co. Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see DongKook Pharmaceutical Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩763.74 Billion ≈ $517.57 Million |
₩68.76 Billion ≈ $46.60 Million |
0.090x | -19.66% |
| 2024-12-31 | ₩678.98 Billion ≈ $460.13 Million |
₩76.09 Billion ≈ $51.57 Million |
0.112x | +54.50% |
| 2023-12-31 | ₩576.17 Billion ≈ $390.46 Million |
₩41.79 Billion ≈ $28.32 Million |
0.073x | -11.00% |
| 2022-12-31 | ₩501.94 Billion ≈ $340.16 Million |
₩40.91 Billion ≈ $27.72 Million |
0.082x | -17.03% |
| 2021-12-31 | ₩454.57 Billion ≈ $308.05 Million |
₩44.65 Billion ≈ $30.26 Million |
0.098x | -31.63% |
| 2020-12-31 | ₩411.37 Billion ≈ $278.78 Million |
₩59.11 Billion ≈ $40.06 Million |
0.144x | -24.96% |
| 2019-12-31 | ₩362.87 Billion ≈ $245.91 Million |
₩69.48 Billion ≈ $47.09 Million |
0.191x | +80.48% |
| 2018-12-31 | ₩313.02 Billion ≈ $212.13 Million |
₩33.21 Billion ≈ $22.51 Million |
0.106x | -2.29% |
| 2017-12-31 | ₩263.94 Billion ≈ $178.87 Million |
₩28.66 Billion ≈ $19.42 Million |
0.109x | -34.62% |
| 2016-12-31 | ₩237.32 Billion ≈ $160.83 Million |
₩39.41 Billion ≈ $26.71 Million |
0.166x | +22.14% |
| 2015-12-31 | ₩199.62 Billion ≈ $135.28 Million |
₩27.14 Billion ≈ $18.39 Million |
0.136x | +5.59% |
| 2014-12-31 | ₩176.57 Billion ≈ $119.66 Million |
₩22.74 Billion ≈ $15.41 Million |
0.129x | +5.20% |
| 2013-12-31 | ₩162.24 Billion ≈ $109.95 Million |
₩19.86 Billion ≈ $13.46 Million |
0.122x | -- |
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more